![]() ![]() 1 Early-stage disease is associated with an excellent prognosis. Introduction and Rationale for the Use of Immunotherapy in Endometrial CancerĮndometrial cancer is the most common gynecologic malignancy in postmenopausal women. Continued basic, translational, and clinical research holds the promise to change the landscape of gynecologic cancer and improve the lives of all women impacted by these diseases. We particularly highlight the advent of immunotherapy in endometrial cancer radiosensitizers in cervical, vaginal, and vulvar cancers targeted therapies in ovarian cancer and molecularly driven approaches to treat rare gynecologic cancers. We highlight research that has deepened our understanding of the unique biology and molecular underpinnings of these cancers and is being translated into powerful new treatment approaches. ![]() ![]() Here, we discuss emerging treatments for gynecologic cancers, including endometrial, cervical, ovarian, and rare gynecologic cancers. ![]() Fortunately, exciting work defining new therapeutic targets and novel treatment strategies is on the horizon. However, continued advancement in the treatment of gynecologic cancers is critical. The advent of PARP inhibitors, antiangiogenic therapies, immunotherapy combinations, and targeted agents have altered the standard of care in ovarian, endometrial, and cervical cancers. During the past decade, considerable strides have been made in the understanding and treatment of gynecologic cancers. ![]()
0 Comments
Leave a Reply. |